<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>bladder cancer heterogeneity &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/bladder-cancer-heterogeneity/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 12:39:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>bladder cancer heterogeneity &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Transcription Factor Subtypes in Bladder Cancer</title>
		<link>https://bioengineer.org/transcription-factor-subtypes-in-bladder-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 24 Apr 2025 09:37:55 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[bladder cancer heterogeneity]]></category>
		<category><![CDATA[bladder vs prostate cancer subtypes]]></category>
		<category><![CDATA[immunohistochemistry in cancer studies]]></category>
		<category><![CDATA[neuroendocrine tumors in bladder]]></category>
		<category><![CDATA[transcription factor subtypes in oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/transcription-factor-subtypes-in-bladder-cancer/</guid>

					<description><![CDATA[In the ever-evolving landscape of oncology, small cell carcinoma (SmCC) of the bladder remains one of the most enigmatic and aggressive forms of malignancy. Its rarity poses significant challenges to both diagnosis and treatment, often leaving clinicians grappling with limited understanding and therapeutic options. However, a groundbreaking study emerging from Japan promises to shed new [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">242022</post-id>	</item>
	</channel>
</rss>
